@article{oai:hirosaki.repo.nii.ac.jp:00003788,
 author = {Yoneyama, Tohru and Hatakeyama, Shingo and Yamamoto, Hayato and Imanishi, Kengo and Okamoto, Teppei and Tokui, Noriko and Sugiyama, Naoki and Suzuki, Yuichiro and Kudo, Shigemasa and Hashimoto, Yasuhiro and Koie, Takuya and Kamimura, Noritaka and Fukuda, Michiko N. and Ohyama, Chikara},
 issue = {Supplement},
 journal = {弘前医学},
 month = {Apr},
 note = {Background. Antibody-mediated rejection （AMR） after ABO-incompatible kidney transplantation （ABO-I KTx） is a major barrier to the success of transplantation. The advent of immunosuppressive therapy has markedly improved graft survival in ABO-I KTx. However, compare with a normal KTx, clinical conditions during ABO-IKTx are difficult to control due to over-immunosuppression. To reduce the immunosuppression we try to develop the blood group antigen-neutralizing therapy.
Methods. We screened an ABO blood group antigen targeting peptide （BATP） by peptide library displayed T7 phage screening. After screening, a hemagglutination（ HA） inhibition assay and ELISA assay was used to analyze the blood group antigen blocking effect of the BATP. We also tested the inhibitory effect of anti-blood group Ab binding in normal human kidney tissues blocked with BATP.
Results. We identified six peptide sequences. BATP efficiently suppresses hemagglutination of red blood cells caused by anti-ABO blood group antibodies and binding of these antibodies to ABO histo-blood group antigens on kidney tissue.
Conclusions. These data indicating that blood group A/B-antigen on RBCs and on kidney tissues may neutralize by BATP. This approach may enable the development of novel blood group antigen neutralizing therapy to overcome the challenges of ABO-I KTx., 弘前医学. 64(Suppl.), 2013, p.S121-S128},
 pages = {S121--S128},
 title = {Blood Group Antigen Targeting Peptide Suppresses Thrombotic Microangiopathy in Renal Glomerular Capillaries after ABO-Incompatible Blood Reperfusion},
 volume = {64},
 year = {2013}
}